Loading data for ORMP — first visit, this takes a few seconds.

Alerta

Oramed Pharmaceuticals In... (ORMP)

NasdaqCM: ORMP · Precio en tiempo real · USD

4.78

+0.21 (4.60%)

Al cierre: Aug 18, 2026, 8:00 PM

4.83

+1.05%

Premercado: 7:27 AM

4.60% (1D)

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	198.84M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	174.06M
Beta	1.16
EPS (TTM)	4.13
Ratio PER (TTM)	1.16
Adelante PE	-59.75
P/B (TTM)	0.62
P/S (TTM)	n/a
Earnings Date	Nov 12, 2026

Precio de venta	n/a
Volumen	297,698
Volumen medio (20D)	292,669
Abierto	4.56
Anterior Cerrar	4.57
Rango del día	4.48 - 4.82
Rango de 52 semanas	2.05 - 5.19
analista	n/a
Precio objetivo	n/a
Dividendos	$0.25 (5.22%)
Fecha ex dividendo	16 ene 2026

Acerca de ORMP

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporat...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha May 1, 2007

Empleados n/a

Bolsa de Valores NasdaqCM

Símbolo bursátil ORMP

Sitio web https://oramed.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Oramed Pharmaceuticals fueron 2M, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron 64.05M, una disminución de -436.04%.

Estados financieros

Sorpresa de resultados

Oramed Pharmaceuticals ha publicado sus resultados trimestrales en Aug 10, 2026:

Ingresos de $0 falla las estimaciones por $0, con -100.00% Disminución interanual.

EPS de 1.84 supera las estimaciones en 1.41, con 1068.42% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Oramed Pharmaceuticals Inc. publique sus resultados el Nov 12, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

2 meses hace · Simply Wall St.

June 2026 Penny Stocks To Watch For Potential Growth

Over the last 7 days, the market has remained flat, but it is up 24% over the past year, with earnings expected to grow by 19% per annum over the next few years. For investors willing to explore beyon...

3 meses hace · Simply Wall St.

Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks

The market has climbed 1.5% in the last 7 days and is up 26% over the last 12 months, with earnings forecast to grow by 17% annually. While the term 'penny stock' might seem outdated, these investment...

4 meses hace · Simply Wall St.

Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors

The market has shown impressive growth, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are projected to grow by 16% annually. Although the term 'penny stock'...

4 meses hace · Associated Press Finance

Oramed: Q4 Earnings Snapshot

NEW YORK (AP) — Oramed Pharmaceuticals Inc. ORMP) on Thursday reported profit of $10 million in its fourth quarter. The New York-based company said it had net income of 24 cents per share.

6 meses hace · Motley Fool

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround

CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.

Página 1 de 2